TAT and neoplasm: Tumor volume and weight measurements at the end of the therapy revealed a statistically significant reduction in mean tumor weight in the miRNA-34a/Tat-A86 group (0.37 g) compared to both the miRNA/Tat-E60 group (0.56 g) and the untreated cohort (~ 0.94 g) (Fig. 9e).